Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients

PURPOSE: Regorafenib is an oral multikinase inhibitor approved for the therapy of previously treated metastatic colorectal carcinoma (mCRC). The aim of the present study was to analyze the outcomes of treatment with regorafenib in real-world clinical practice based on data from a national registry....

Descripción completa

Detalles Bibliográficos
Autores principales: Novakova-Jiresova, Alena, Kopeckova, Katerina, Boublikova, Ludmila, Chloupkova, Renata, Melichar, Bohuslav, Petruzelka, Lubos, Finek, Jindrich, Fiala, Ondrej, Grell, Peter, Batko, Stanislav, Linke, Zdenek, Kiss, Igor, Prausova, Jana, Buchler, Tomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342462/
https://www.ncbi.nlm.nih.gov/pubmed/32753954
http://dx.doi.org/10.2147/CMAR.S255332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342462/
https://www.ncbi.nlm.nih.gov/pubmed/32753954
http://dx.doi.org/10.2147/CMAR.S255332

Ejemplares similares